-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Immuneering, Raises Price Target to $10

Benzinga·06/18/2025 14:46:52
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Immuneering (NASDAQ:IMRX) with a Outperform and raises the price target from $8 to $10.